HYAL2的甲基化状态可预测接受5-氟尿嘧啶化疗的结肠癌患者的总生存期和无进展生存期。

Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy.

作者信息

Pfütze Katrin, Benner Axel, Hoffmeister Michael, Jansen Lina, Yang Rongxi, Bläker Hendrik, Herpel Esther, Ulrich Alexis, Ulrich Cornelia M, Chang-Claude Jenny, Brenner Hermann, Burwinkel Barbara

机构信息

Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center (DKFZ), Germany; Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Germany.

Division of Biostatistics, German Cancer Research Center (DKFZ), Germany.

出版信息

Genomics. 2015 Dec;106(6):348-54. doi: 10.1016/j.ygeno.2015.10.002. Epub 2015 Oct 21.

DOI:10.1016/j.ygeno.2015.10.002

PMID:26453961

Abstract

DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.

摘要

基因启动子区域的DNA甲基化变异是包括结肠癌在内的人类恶性肿瘤中充分记录的肿瘤特异性改变，这可能会影响肿瘤行为和临床结果。由于一部分结肠癌患者不能从辅助化疗中获益，因此需要预测性生物标志物。在此，我们描述了透明质酸葡萄糖胺酶2（HYLA2）的CpG位点的DNA甲基化水平可用于识别II期和III期结肠癌患者，这些患者在总生存期和无进展生存期方面最有可能从5-氟尿嘧啶（5-FU）化疗中获益。